Precision medicine in inflammatory bowel diseases.

Area of Science:

• Gastroenterology
• Immunology
• Genomics

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are increasingly prevalent global health issues.
• Advances in therapeutic mechanisms have improved remission rates and reduced disease-related morbidity.
• Current data is insufficient to guide the optimal sequencing of these diverse therapies for individual patients.

Purpose of the Study:

• To review clinical decision models for comparing therapeutic efficacy based on patient characteristics.
• To highlight the utility of biomarkers (serologic, transcriptomic, microbiome) in predicting treatment response.
• To identify literature gaps and propose future research directions for precision medicine in IBD management.

Main Methods:

• Literature review of clinical decision models in IBD therapy.
• Analysis of studies utilizing biomarkers for treatment selection.
• Synthesis of existing evidence to identify research gaps.

Main Results:

• Clinical decision models show promise in guiding therapy selection.
• Biomarkers such as serologic, transcriptomic, and microbiome profiles can predict individual treatment efficacy.
• Significant gaps exist in understanding the comparative effectiveness of different therapeutic mechanisms.

Conclusions:

• Integrating clinical decision models and biomarkers is crucial for personalized IBD management.
• Future research should focus on validating these approaches to optimize patient care.
• Adopting precision medicine principles can enhance treatment outcomes for IBD patients.